Your innovative therapy is ready to reach a key milestone with the IND date quickly approaching. You need a reliable partner to formulate and manufacture your therapy to meet the IND filing requirements and the dose needs for phase I studies fast.
Every innovation is unique so your partner needs to offer the right mix of formulation and dosage form options and rapidly use data-driven models to determine the best option – not a one-size-fits-all mindset.
WuXi STA's F2CS package applies our capability, expertise and advanced technology to deliver effective clinical trial material fast. F2CS is the abbreviation of "Fast to Clinical Supply", representing the promise of formulation development and CTM supply both within 8 weeks.
WuXi STA teams are highly experienced with 1,000+ scientists, delivering 2,800+ CTM batches in 2022 across a wide variety of molecules in different dosage forms. Our integrated teams develop the most appropriate formulations exploring a variety of dosage forms tools including a complete bioavailability enhancement toolbox for fast delivery of CTM for the best chance of success.
Fast - Our integrated drug substance, drug product, analytical, and CMC writing teams work in parallel to save time and complete your project fast. Our large team and facility capacity are able to accommodate unexpected changes fast to ensure on time and on budget delivery. 
Flexible - Our facilities and team are equipped and experienced with a wide variety of dosage forms and processing tools. They have access to the most advanced bioavailability enhancing technologies enabling the selection and design of a dosage form that best meets optimal exposure.
Integrated – Drug product and analytical teams are located at the same site with drug substance teams within 2 hour drive, making collaboration, problem-solving, scheduling, and material transfer fast and simple.
{{art.articleContent}}
{{art.subTitle}}
{{fa.cardTitle}}
{{fa.cardTitle}}
{{art.articleTitle}}
{{art.subTitle}}